DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Miscellaneous BB Biotech AG admitted to the SMIM and SPI Index 09-Jul-2018 / 18:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Media release as of July 9, 2018 BB Biotech AG admitted to the SMIM and SPI Index After the SIX Swiss Exchange's latest regular review of index components, BB Biotech was admitted to the SMIM Index and the SPI Index (sub-index SPI Mid). The composition of the two indices will be adjusted after the close of trading on September 21, 2018, effective as of September 24, 2018. BB Biotech was previously admitted to the Stoxx Europe 600 in 2014 due to its growing market capitalization and trading liquidity. "BB Biotech's admission to the SMIM Index reflects our successful performance in the highly attractive market of biotechnology," declares Dr. Daniel Koller, Head of BB Biotech's Investment Team. "With almost 25 years of experience and an investment portfolio of around CHF 3.5 bn, we are one of the largest investors in this field." The SMI family, the most widely followed group of indices compiled by SIX Swiss Exchange, comprises the 50 largest and most liquid stocks in the Swiss stock market. The blue-chip SMI Index is the most prestigious index of stocks listed in Switzerland and comprises the 20 largest stocks from the SPI. The SMIM, in which BB Biotech will be a member effective September 24, 2018, comprises the next 30 largest and most liquid stocks from the mid cap segment of the SPI. All SMI and SMIM stocks are included in the SMI Expanded Index, which covers more than 90% of the Swiss stock market's entire capitalization. For further information: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07 Tanja Chicherio, [email protected] TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28 Thomas Egger, [email protected] www.bbbiotech.com Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science. --------------------------------------------------------------------------- 09-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen Switzerland Phone: +41 52 624 08 45 E-mail: [email protected] Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX End of Announcement DGAP News Service --------------------------------------------------------------------------- 702815 09-Jul-2018 CET/CEST